FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281677251> ?p ?o ?g. }

• W4281677251 endingPage "9524" @default.
• W4281677251 startingPage "9524" @default.
• W4281677251 abstract "9524 Background: Cutaneous melanoma is characterized by high TMB, which is associated with increased tumor-specific neoantigen expression (Schumacher Science 2015) and an increased response rate to ICI (Yarchoan NEJM 2019). The TMB in tumors that recur/progress after ICI is not well defined. Lifileucel is a one-time, autologous TIL cell therapy under investigation for treatment of patients (pts) with advanced melanoma. We conducted a matched case-control study of prospectively enrolled pts with advanced melanoma treated with lifileucel in the ICI-naïve (IOV-COM-202 trial, Cohort 1A [C1A]) and post-ICI (C-144-01 trial, Cohort 2 [C2]) setting to investigate the potential association between prior ICI therapy, TMB, and response to lifileucel. Methods: All pts had unresectable or metastatic melanoma. Available cases from C1A (ICI-naïve pts receiving lifileucel + pembrolizumab [pembro]) were matched to controls from C2 (pts receiving lifileucel alone after progression on anti–PD-1/PD-L1 therapy); 3 controls per case were matched at least for BRAF status and disease stage at study entry, and if possible, for anatomic site of tumor harvest. Lifileucel regimen was similar in C1A and C2. In C1A, 1 dose of pembro was given after tumor harvest and before nonmyeloablative lymphodepletion and resumed after lifileucel per standard treatment, for up to 2 y. Objective response rate (ORR) was assessed by investigators per RECIST v1.1. TMB of the resected tumor was measured using the ImmunoID NeXT (C1A) or PGDx elio (C2) platform; a validated conversion factor was used to compare TMB between platforms (Vega Ann Oncol 2021). High TMB was defined as ≥10 mut/MB. Results: Seven pts in C1A and 21 in C2 were included in the case-control study and had ORR of 71.4% and 38.1%, respectively. The percentage of pts with high TMB was 57.1% in C1A and 19.0% in C2 ( P = 0.1). ORR in the low and high TMB groups was 66.7% and 75.0%, respectively, in C1A and 41.1% and 25.0% in C2; 60% of responders in C1A and 12.5% in C2 had high TMB. In logistic regression analysis adjusted for cohort, TMB was not associated with response to lifileucel (odds ratio, 1.0; 95% CI, 0.9–1.1; P = 0.8). Data on tumor mutations and neoantigens, T-cell receptor repertoire, and tumor microenvironment profile will be presented. Conclusions: Our preliminary data indicate that the efficacy (ORR) of lifileucel may be independent of TMB, regardless of treatment setting, consistent with its proposed immune checkpoint pathway-independent mechanism of action. The percentage of patients with high TMB tended to be lower in tumors with prior ICI exposure than in those that were ICI-naïve. Clinical trial information: NCT03645928; NCT02360579." @default.
• W4281677251 created "2022-06-13" @default.
• W4281677251 creator A5000718315 @default.
• W4281677251 creator A5001155783 @default.
• W4281677251 creator A5001175430 @default.
• W4281677251 creator A5003681868 @default.
• W4281677251 creator A5004458225 @default.
• W4281677251 creator A5010628808 @default.
• W4281677251 creator A5014305948 @default.
• W4281677251 creator A5016263949 @default.
• W4281677251 creator A5020117122 @default.
• W4281677251 creator A5028391998 @default.
• W4281677251 creator A5033965725 @default.
• W4281677251 creator A5035859456 @default.
• W4281677251 creator A5036480949 @default.
• W4281677251 creator A5047177507 @default.
• W4281677251 creator A5049158933 @default.
• W4281677251 creator A5065290717 @default.
• W4281677251 creator A5070008988 @default.
• W4281677251 creator A5086165685 @default.
• W4281677251 creator A5090633646 @default.
• W4281677251 date "2022-06-01" @default.
• W4281677251 modified "2023-10-16" @default.
• W4281677251 title "Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy." @default.
• W4281677251 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9524" @default.
• W4281677251 hasPublicationYear "2022" @default.
• W4281677251 type Work @default.
• W4281677251 citedByCount "2" @default.
• W4281677251 countsByYear W42816772512022 @default.
• W4281677251 countsByYear W42816772512023 @default.
• W4281677251 crossrefType "journal-article" @default.
• W4281677251 hasAuthorship W4281677251A5000718315 @default.
• W4281677251 hasAuthorship W4281677251A5001155783 @default.
• W4281677251 hasAuthorship W4281677251A5001175430 @default.
• W4281677251 hasAuthorship W4281677251A5003681868 @default.
• W4281677251 hasAuthorship W4281677251A5004458225 @default.
• W4281677251 hasAuthorship W4281677251A5010628808 @default.
• W4281677251 hasAuthorship W4281677251A5014305948 @default.
• W4281677251 hasAuthorship W4281677251A5016263949 @default.
• W4281677251 hasAuthorship W4281677251A5020117122 @default.
• W4281677251 hasAuthorship W4281677251A5028391998 @default.
• W4281677251 hasAuthorship W4281677251A5033965725 @default.
• W4281677251 hasAuthorship W4281677251A5035859456 @default.
• W4281677251 hasAuthorship W4281677251A5036480949 @default.
• W4281677251 hasAuthorship W4281677251A5047177507 @default.
• W4281677251 hasAuthorship W4281677251A5049158933 @default.
• W4281677251 hasAuthorship W4281677251A5065290717 @default.
• W4281677251 hasAuthorship W4281677251A5070008988 @default.
• W4281677251 hasAuthorship W4281677251A5086165685 @default.
• W4281677251 hasAuthorship W4281677251A5090633646 @default.
• W4281677251 hasConcept C121608353 @default.
• W4281677251 hasConcept C126322002 @default.
• W4281677251 hasConcept C143998085 @default.
• W4281677251 hasConcept C2777658100 @default.
• W4281677251 hasConcept C2777701055 @default.
• W4281677251 hasConcept C2778326572 @default.
• W4281677251 hasConcept C2780057760 @default.
• W4281677251 hasConcept C2781413609 @default.
• W4281677251 hasConcept C502942594 @default.
• W4281677251 hasConcept C71924100 @default.
• W4281677251 hasConcept C72563966 @default.
• W4281677251 hasConceptScore W4281677251C121608353 @default.
• W4281677251 hasConceptScore W4281677251C126322002 @default.
• W4281677251 hasConceptScore W4281677251C143998085 @default.
• W4281677251 hasConceptScore W4281677251C2777658100 @default.
• W4281677251 hasConceptScore W4281677251C2777701055 @default.
• W4281677251 hasConceptScore W4281677251C2778326572 @default.
• W4281677251 hasConceptScore W4281677251C2780057760 @default.
• W4281677251 hasConceptScore W4281677251C2781413609 @default.
• W4281677251 hasConceptScore W4281677251C502942594 @default.
• W4281677251 hasConceptScore W4281677251C71924100 @default.
• W4281677251 hasConceptScore W4281677251C72563966 @default.
• W4281677251 hasIssue "16_suppl" @default.
• W4281677251 hasLocation W42816772511 @default.
• W4281677251 hasOpenAccess W4281677251 @default.
• W4281677251 hasPrimaryLocation W42816772511 @default.
• W4281677251 hasRelatedWork W2342781363 @default.
• W4281677251 hasRelatedWork W2607780130 @default.
• W4281677251 hasRelatedWork W2903811712 @default.
• W4281677251 hasRelatedWork W2932125351 @default.
• W4281677251 hasRelatedWork W2969782175 @default.
• W4281677251 hasRelatedWork W3153432702 @default.
• W4281677251 hasRelatedWork W3161613553 @default.
• W4281677251 hasRelatedWork W3215044659 @default.
• W4281677251 hasRelatedWork W4225127290 @default.
• W4281677251 hasRelatedWork W4292373623 @default.
• W4281677251 hasVolume "40" @default.
• W4281677251 isParatext "false" @default.
• W4281677251 isRetracted "false" @default.
• W4281677251 workType "article" @default.